Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05361174 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Jun 2025 to Sep 2027 Study sites: 10 to 11 · Completion date: Jun 2027 to Sep 2029v13 Show 2 more changesShow less
    • Study sites: 10 to 11
    • Completion date: Jun 2027 to Sep 2029
  2. Site details revised at 1 of 10 sitesv12
  3. Study sites: 9 to 10 Eligibility criteria expanded, about 15 words · Secondary endpoints: details revised at 1 of 7 entriesv11 Show 2 more changesShow less
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 1 of 7 entries

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 8 to 9v10
  5. Re-verified, no change to tracked fieldsv9
Show 7 earlier versionsHide 7 earlier versions
  1. Study sites: 7 to 8v8
  2. Study sites: 5 to 7v7
  3. Study sites: 4 to 5v6
  4. Study sites: 3 to 4v5
  5. Study sites: 2 to 3v4
  6. Study sites: 1 to 2 Start date changed from estimate of Jun 2022 to Jul 20, 2022v3 Show 1 more changeShow less
    • Start date changed from estimate of Jun 2022 to Jul 20, 2022
  7. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v2 Show 1 more changeShow less
    • Study sites: 0 to 1
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).
Trial Details
NCT Number NCT05361174
Lead Sponsor Iovance Biotherapeutics, Inc.
Conditions Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Enrollment 53 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov